oxybutynin has been researched along with Nycturia in 9 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of oxybutynin patch versus β3-adrenoceptor agonist mirabegron on nocturia-related quality of life in female overactive bladder patients." | 9.41 | Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: A multicenter randomized trial. ( Furuhata, M; Hosaka, K; Ishizuka, O; Minagawa, T; Nakagawa, T; Ogawa, T; Saito, T; Suzuki, T, 2021) |
| "To investigate the efficacy of a once-daily oxybutynin patch for nocturia, and its influence on sleep quality in patients with overactive bladder." | 9.20 | Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial. ( Higo, N; Ishizuka, O; Masegi, Y; Minami, H; Seki, N; Takahashi, S; Yamaguchi, A; Yamaguchi, O; Yamanishi, T; Yokoyama, O; Yoshida, M, 2015) |
| "To investigate the effect of oxybutynin patch versus β3-adrenoceptor agonist mirabegron on nocturia-related quality of life in female overactive bladder patients." | 5.41 | Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: A multicenter randomized trial. ( Furuhata, M; Hosaka, K; Ishizuka, O; Minagawa, T; Nakagawa, T; Ogawa, T; Saito, T; Suzuki, T, 2021) |
| "To investigate the efficacy of a once-daily oxybutynin patch for nocturia, and its influence on sleep quality in patients with overactive bladder." | 5.20 | Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial. ( Higo, N; Ishizuka, O; Masegi, Y; Minami, H; Seki, N; Takahashi, S; Yamaguchi, A; Yamaguchi, O; Yamanishi, T; Yokoyama, O; Yoshida, M, 2015) |
| " The AMs used to treat OAB differ in their pharmacological profiles, which may affect their potential for causing adverse effects (AEs)." | 2.48 | Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. ( Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Fralick, M | 1 |
| Schneeweiss, S | 1 |
| Wallis, CJD | 1 |
| Jung, EH | 1 |
| Kesselheim, AS | 1 |
| Suzuki, T | 2 |
| Minagawa, T | 1 |
| Saito, T | 1 |
| Nakagawa, T | 1 |
| Furuhata, M | 1 |
| Hosaka, K | 1 |
| Ogawa, T | 1 |
| Ishizuka, O | 2 |
| Johnson, TM | 1 |
| Markland, AD | 1 |
| Goode, PS | 1 |
| Vaughan, CP | 1 |
| Colli, JL | 1 |
| Ouslander, JG | 1 |
| Redden, DT | 1 |
| McGwin, G | 1 |
| Burgio, KL | 1 |
| Yokoyama, O | 1 |
| Yamaguchi, A | 1 |
| Yoshida, M | 1 |
| Yamanishi, T | 1 |
| Seki, N | 1 |
| Takahashi, S | 1 |
| Yamaguchi, O | 2 |
| Higo, N | 2 |
| Minami, H | 2 |
| Masegi, Y | 1 |
| Uchida, E | 1 |
| Kobayashi, S | 1 |
| Sato, H | 1 |
| Ellsworth, P | 1 |
| Caldamone, A | 1 |
| Wong, C | 1 |
| Duggan, P | 1 |
| Newman, DK | 1 |
| Leone Roberti Maggiore, U | 1 |
| Salvatore, S | 1 |
| Alessandri, F | 1 |
| Remorgida, V | 1 |
| Origoni, M | 1 |
| Candiani, M | 1 |
| Venturini, PL | 1 |
| Ferrero, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Behavioral Treatment of Overactive Bladder in Men[NCT01187498] | Phase 3 | 143 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean voiding frequency per 24 hours derived from 7-day bladder dairy (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | voids per 24-hour day (Mean) |
|---|---|
| Behavioral Training | 9.1 |
| Drug Therapy | 9.5 |
Change in frequency of nocturia episodes based on 7-day bladder diary (NCT01187498)
Timeframe: baseline to post-treatment (week 8)
| Intervention | nocturia episodes per night (Mean) |
|---|---|
| Behavioral Training | -0.70 |
| Drug Therapy | -.32 |
"Indevus Urgency Severity Scale incorporated into the 7-day bladder diary. Scores for urgency severity ranged from 0 to 3:~0: None-no urgency~Mild-awareness of urgency, but is easily tolerated.~Moderate-enough urgency discomfort that it interferes with or shortens usual activity~Severe-extreme urgency discomfort that abruptly stops all activities or tasks." (NCT01187498)
Timeframe: baseline to post-treatment (week 8)
| Intervention | Score on scale (Mean) |
|---|---|
| Behavioral Training | .04 |
| Drug Therapy | -.15 |
Change in score on American Urological Association (AUA) Symptom Index (baseline to week 8). The index measures lower urinary tract symptoms. Scores range from 0 to 35, with higher scores indicating worse symptoms. (NCT01187498)
Timeframe: baseline to post-treatment (week 8)
| Intervention | Scores on the scale (Mean) |
|---|---|
| Behavioral Training | 3.4 |
| Drug Therapy | 3.2 |
"Patient response to Do you wish to receive another form of treatment? (yes)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) |
|---|---|
| Behavioral Training | 18 |
| Drug Therapy | 30 |
Percent change in frequency of urge incontinence episodes based on 7-day bladder diary. Percent change was calculated as ([frequency at baseline] - [frequency at 8 weeks]) / (frequency at baseline). (NCT01187498)
Timeframe: baseline to post-treatment (week 8)
| Intervention | Percent change in episodes per week (Mean) |
|---|---|
| Behavioral Training | 87.2 |
| Drug Therapy | 75.6 |
"Patient global perception of improvement (much better to much worse)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Much better | Better | About the same | Worse | Much worse | |
| Behavioral Training | 23 | 30 | 10 | 0 | 0 |
| Drug Therapy | 18 | 34 | 7 | 1 | 0 |
"Patient global rating of activity restriction (not at all to all the time)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not at all | Slightly | Some of the time | All the time | |
| Behavioral Training | 29 | 19 | 11 | 4 |
| Drug Therapy | 31 | 15 | 13 | 1 |
"Patient global rating of how bothersome their side effects were (no side effects to extremely bothersome)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| No side effects | Not at all bothersome | A Little | Somewhat | Extremely | |
| Behavioral Training | 23 | 16 | 16 | 7 | 1 |
| Drug Therapy | 11 | 13 | 19 | 13 | 4 |
"Patient report of how disturbed they were by symptoms (not at all to extremely)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not at all | Slightly | Somewhat | All the time | |
| Behavioral Training | 19 | 30 | 14 | 0 |
| Drug Therapy | 17 | 35 | 7 | 1 |
"Patient global rating of satisfaction with progress in treatment (completely satisfied to very dissatisfied)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Completely satisfied | Somewhat satisfied | Somewhat dissatisfied | Very Dissatisfied | |
| Behavioral Training | 36 | 25 | 2 | 0 |
| Drug Therapy | 25 | 33 | 2 | 0 |
1 review available for oxybutynin and Nycturia
| Article | Year |
|---|---|
Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Chronic Disease; Cresols; Drug Combinations; Female; | 2012 |
5 trials available for oxybutynin and Nycturia
| Article | Year |
|---|---|
Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: A multicenter randomized trial.
Topics: Acetanilides; Double-Blind Method; Female; Humans; Mandelic Acids; Nocturia; Quality of Life; Thiazo | 2021 |
Efficacy of adding behavioural treatment or antimuscarinic drug therapy to α-blocker therapy in men with nocturia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Behavior Therapy; Dose-Response Relati | 2013 |
Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Double-Blind Method; Female; Humans; Japan; Male; Mand | 2015 |
Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Female; Humans; M | 2016 |
Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
Topics: Adult; Aged; Cholinergic Antagonists; Female; Humans; Mandelic Acids; Middle Aged; Nocturia; Pilot P | 2009 |
3 other studies available for oxybutynin and Nycturia
| Article | Year |
|---|---|
Desmopressin and the risk of hyponatremia: A population-based cohort study.
Topics: Administration, Intranasal; Aged; Aged, 80 and over; Cohort Studies; Deamino Arginine Vasopressin; F | 2019 |
Pediatric voiding dysfunction: a case study.
Topics: Adolescent; Behavior Therapy; Causality; Cholinergic Antagonists; Combined Modality Therapy; Constip | 2008 |
The MATRIX study: evaluating the data in older adults.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Attitude to Health; Dementia; Diapers, Ad | 2008 |